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AB S T R A CT  
Alzheimer’s disease is one form of dementia affecting a significant proportion of the population. The 
etiology of this prevalent disease is currently unknown. It is postulated that AD can be treated by using 
stem cell-based therapies by replacing the lost neurons in the atrophic regions of the brain. For these 
novel therapies to be successful several sources of stem cells have been proposed, such as pluripotent 
stem cells as well as multipotent stem cells. Proof of concept in animal studies have shown that stem 
cells can grafted into the affected regions or delivered intravenously into affected parts of the brain. 
These experiments had improved cognition and memory performance in rodents. The promising 
results seen in animal models have increased interest in conducting clinical trials using the same 
technique. In the last 5 years several treatments have reached phase II clinical trials.   
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1 Introduction  
The prevalence of dementia is a major concern 
for the public health agencies all over the world. 
Current estimates state over 50 million people 
suffer from dementia globally and is expected to 
increase due to ageing of the population [1]. One 
form of dementia is due to Alzheimer’s disease 
(AD), which is one of the leading causes of death 
in the United States [2]. The disease is 
characterized by significant atrophy in the 
subcortex and cerebral cortex. In the early stages 
of the disease patients display mild cognitive 
impairment, such as having problems with their 
short-term memory, semantic memory etc. As 
the disease progresses patients have shrinking 
vocabulary, problems communicating and the 
loss of long-term memory. In the advanced stages 
the patients become bedridden and unable to take 
care of themselves (Table 1) [3].  
AD is classified as early onset or late onset, the 
latter constitutes of most of the AD cases. A 
significant proportion of early onset AD is 
familial and is manifested due to mutations in 
three genes: amyloid-β precursor protein (AβPP), 
presenilin-1 (PS-1) and presenilin-2 (PS-2) [4]. 
Gene knockout studies have shown that APP is 
involved in synapse formation [5]. Moreover 
AβPP is a precursor molecule that is further 
cleaved by secretases (such as alpha-secretase, 
beta secretase and gamma secretase). When 
AβPP is cleaved by β-secretase and γ-secretase 
amyloid beta (Aβ) is formed [6]. 
Currently the pathology of the disease is heavily 
debated. One of the premises of the disease is 
called the amyloid hypothesis, with the latest 
iteration being referred as the ion channel 
hypothesis. The notion of the hypothesis is that 
non-fibrillar and soluble Aβ oligomer is the most 
neurotoxic by forming membrane ion channels in 
the neurons. This allow unregulated calcium 
influx, leading to neuronal death [7], [8]. However 
not all AD diagnosed patients show presence of 
Aβ. This can be exemplified by Doraiswamy’s 
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and colleague’s research conducted at Harvard. 
By using a molecule that binds to Aβ called 
Florbetapir they showed that PET scans of one 
third of AD patients recruited in the study did not 
show signs of Aβ in their PET scans [9]. 
Moreover pharmacological targets identified by 
adhering to the amyloid hypothesis lead to failed 
clinical outcomes in clinical trials. In one phase I 
clinical trial of an experimental vaccine (AN1792) 
for clearing up amyloid plaques failed to slow 
down the progression of AD [10]. Recent phase 
III clinical trials have followed the same trend. 
Verubecestat, which inhibits Aβ production by 
acting as an inhibitor for β-secretase, has failed in 
a phase III clinical trial [11], [12].  Similarly, a 
biologic was promising in animal models of AD 
but a phase III drug trial was terminated early due 
to lack of evidence [13]. Because of failure of drug 
development for treating AD there has been a 
renewed interest in stem cell-based therapies. In 
this review we will discuss the different sources 
of stem cells that can be used, proof of concept 
experiments using animal models and finally 
explore clinical trials being conducted on stem 
cell-based treatments for AD. 
Table 1: Progression of symptoms in AD. Adapted 
from Alistair Burns & Steve [3]. 
2 Sources of Stem Cells 
Stem cells are undifferentiated cells that have the 
ability to differentiate into specialized cells or 
replicate to generate more stem cells. They can be 
grouped into two types: pluripotent or 
multipotent according to their potential for 
differentiation. Examples of pluripotent stem 
cells are embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSCs) whilst 
examples of multipotent stem cells are neural 
stem cells (NSCs), mesenchymal stem cells 
(MSCs) etc (Table 2). 
In vivo 5-6 days post fertilisation ESCs are located 
in a clump of cells called inner cell mass of the 
developing embryo. At this point the embryo is 
at the preimplantation stage. Scientists do not 
have to harvest ESCs embryo inside the womb as 
these embryos can be fertilized in vitro and 
expanded in culture indefinitely [14]–[16]. These 
ESCs can be made to differentiate into neurons 
and other cells found in the brain parenchyma, 
such as the glial cells. In fact ESCs can be 
specified into neurons in several ways. One 
approach for specifying ESCs into neural 
progenitors would be to culture ESCs in the 
presence of fetal calf serum augmented by basic 
fibroblast growth factor and epidermal growth 
factor [17], [18]. Similarly another efficient 
method of differentiating ESCs neurons involves 
stromal feeder cells or retinoic acid [19]. Recently 
a technique was developed of differentiation 
involves manipulating Sonic Hedgehog signaling. 
In this specific case ESCs are differentiated into 
cortical neurons by using a inhibitor for sonic 
hedgehog called cyclopamine [20].  
iPSCs are one form of pluripotent stem cells and 
thus have the potential to form all three germ 
layers. These are somatic cells that have been 
reprogrammed into a pluripotent state. iPSCs 
were first created by Yamanka and his group, 
demonstrating that fibroblasts can be converted 
into a stem-like state after adding four 
transcriptional factors: Oct3/4, Sox2, c-Myc, and 
Klf4 [21]. Later Yamanaka and others have 
shown that other types of somatic cells (such as 
hepatocyptes, t-cells, etc.,) can also be 
reprogrammed into iPSCs [22], [23]. One group 
based in has demonstrated that somatic lung 
fibroblasts can be reprogrammed into iPSCs by 
using Oct4, Sox2, Klf4 and c-Myc (the same 
transcription factors used by Yamanaka et al). 
Once successfully reprogrammed these iPSCs 
can be specified into neural fate by blocking 
SMAD signaling with SMAD inhibitors, such as 
Noggin and SB431542 [24].  
 
Disease stage Symptoms 
Mild Alzheimer’s 
disease 
Short term memory loss, 
problems with semantic 
memory, forgetfulness, 
repetitive questioning 
 
Moderate Alzheimer’s 
disease 
Dysexecutive syndrome, 
showing cognitive 
deficits 
Severe Alzheimer’s 
disease 
Assistance required in 
everyday tasks, 
bedbound altered sleep 
pattern, agitation, no 
language skills 
D
isease p
ro
gressio
n
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Table 2: Potential sources of stem cells for treating Alzheimer’s disease. 
Study [18] [20] [24] [28] [29] [35] 
Type of 
stem cell  
Embryonic 
stem cells 
(ESCc) 
Embryonic 
stem cells 
(ESCs) 
Induced 
pluripotent 
stem cells 
(iPSCs) and 
embryonic 
stem cells 
(ESCs) 
 
Neural stem 
cells (NSCs) 
Neural stem 
cells (NSCs) 
Mesenchymal 
stem cells 
(MSCs) 
Method Mouse ESC 4-
day aggregates 
cultured in 5 
X 10-7 M 
retinoic acid 
Mouse ESCs 
cultured in 
serum-free 
and 
morphogen 
free 
chemically 
defined 
default 
medium at low 
density in the 
presence of 1 
μM 
cyclopamine. 
 
Monolayer of 
ESCs or 
iPSCs induced 
into neural 
fate by Noggin 
and 
SB431542. 
NSCs seeded 
on poly-L-
lysine coated 
dish 
differentiated 
into neurons in 
the presence 
of 100 ng/ml 
of interferon-γ 
(IFN—γ). 
Culture NSCs 
in the presence 
of 50 μM of 
Baicalin 
Culture cells 
in the presence 
of 1 mM β-
mercaptoethan
ol for 24 hrs 
Findings 81% ESC 
aggregates 
showed 
neurite 
outgrowths. 
 
39 % of ESC 
aggregates 
differentiated 
into neuron-
like cells.  
 
The neurons-
like cells 
expressed 
class III β 
tubulin, 
neurofilament 
L and M 
subunit, 
glutamate 
receptor 
subunits, 
TTX-sensitive 
sodium 
channels and 
voltage-gated 
potassium 
channels and 
calcium 
channels 
ESCs 
differentiated 
into a 
homogenous 
population of 
neural 
progenitors. 
 
The neural 
progenitors 
expressed 
markers for 
pyramidal 
neurons of the 
cerebral cortex 
(such as 
VGLUT1/2). 
 
After grafting 
the neurons 
showed axonal 
projections, 
which is 
associated 
with different 
layers of the 
cerebral 
cortex. 
Neuroectoder
mal 
differentiation 
was greater 
than 80% 
when both 
Noggin and 
SB431542 
were used. 
 
Neuroectoder
mal 
differentiation 
was less than 
10% when 
either Noggin 
or SB431542 
used. 
 
The Pax 6+ 
neural crest 
cells were 
competent to 
form 
dopaminergic 
and motor 
neurons.  
After neural 
induction of 
NSCs with 
IFN--γ 
 
The number of 
NSCs 
differentiated 
into neurons 
were 8 times 
higher 
compared to 
controls in the 
presence of 
100 ng/ml 
IFN—γ 
differentiated  
 
IFN—γ 
increased the 
expression of 
JNK without 
promoting 
ERK1/2.  
Baicalin 
induced NSCs 
to extend 
neurite 
outgrowth, 
express 
neuronal 
markers and 
neurogenic 
transcriptoinal 
factors 
 
Neuronal 
differentiation 
was induced 
through 
activation of 
Erk1/2. 
80% of MSCs 
differentiated 
into neuronal 
phenotype by 
induction with 
β-
mercaptoethan
ol  
 
Neuronal cells 
expressed 
neurofilament-
M, neuron-
specific 
enolase, tau 
and nestin. 
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Interestingly some somatic cells can be converted 
into a different a lineage directly, avoiding the 
conversion of the stem-like state as seen in iPSC 
reprogramming. Liu and others based in 
University of Colorado have demonstrated that 
fibroblasts can be directly reprogrammed into 
dopaminergic neuron in the presence of five 
transcription factors: Mash1, Ngn2, Sox2, Nurr1, 
and Pitx3 [25]. 
Another type of stem cells are multipotent stem 
cell, which have a limited range of differentiation 
compared to pluripotent stem cells. One example 
of multipotent stem cells is neural stem cells 
(NSCs), which differentiate into astrocytes, 
neurons and oligodendrocytes during 
neurogenesis. Previously it was thought that after 
adolescence the brain is post-mitotic. However 
intricate lineage tracing experiments and 
radioactive Carbon-14 isotope analysis has 
shown that NSCs exist in subventricular zone 
(SVZ) and in the dentate gyrus (DG) of the 
hippocampus of the adult brain generate neurons 
during adulthood [26], [27]. NSCs in the SVZ give 
rise to inhibitory GABAergic and dopaminergic 
interneurons of the olfactory bulb whilst NSCs in 
DG give rise to excitatory glutamatergic granule 
neurons. Moreover NSCs can be readily 
expanded and differentiated into different 
neurons in vitro types making it a potential good 
source of stem cell transplantation for AD. Kim 
et al has shown that NSCs can be readily 
differentiated into neurons in the presence of 
interferon-γ and Li and colleagues have proposed 
that flavonoid Baicalin induces NSCs into 
neurons [28], [29].  
Similarly mesenchymal stem cells are (MSCs) are 
a type of multipotent stem cells. Whether 
mesenchymal stem cells (aka mesenchymal 
stromal cells) are true stem cells are out scope of 
this review. MSCs can be harvested from several 
sources: adipose tissues, placenta, umbilical cord 
blood, bone marrow, muscles etc [30]–[33]. MSCs 
from the adipose tissue is preferred instead of 
bone marrow because the procedure is less 
invasive [34]. MSCs can be advantageous instead 
of using NSCs because of their ability to 
differentiate into multiple lineages including 
neurons. A paper published in 2000 shows that 
that MSCs can differentiate into neural lineages, 
expressing nestin, in the presence of β-
mercaptoethanol [35].  
3 Approaches for Treating AD with Stem 
Cells 
The theoretical approaches for treating AD with 
stem cells can be classified into endogenous 
repair and exogenous repair (Table 3). In 
endogenous repair involves activating the already 
present stem cells, such as NSCs, in the brain. 
Since hippocampal neurogenesis is involved in 
learning and memory it is presumed that 
activating NSCs may halt or at least slow down 
regression of AD. NSCs can be activated and 
upregulated by using growth factors that play a 
role in neurogenesis, such as insulin growth 
factor-1, brain derived neurotrophic factor and 
vascular endothelial growth factor [36].  
Exogenous repair involves stem cell transplants, 
i.e. stem cells are implanted into the atrophic area 
through surgery or injected intravenously. ESCs 
can be one source of stem cells for stem cell 
transplantation. A study published by Yue and 
colleagues have generated basal forebrain 
cholinergic neurons progenitors from ESCs. 
They transplanted the progenitors into the 
forebrain of AD animal rodent models and 
showed that the progenitors functionally 
integrated into the basal forebrain cholinergic 
projection system. Excitingly the mice model 
showed improvements in learning and memory 
[37].  
Another commonly studied stem cell treatments 
in neurodegenerative animal models are MSCs. 
One group based in Egypt (Salem et al) compared 
bone marrow derived mesenchymal stem cells 
(BM-MSCs) with the conventional AD drugs 
(such as rivastigmine and cerebrolysin). They 
showed that the mesenchymal stem cells 
administered intravenously reached the brain. 
Compared to the commonly prescribed drugs for 
AD BM-MSCs showed cognitive improvements 
by upregulating expressions of choline 
acetyltransferase, survivin and nestin, which is a 
marker for neuronal progenitors [38]. Similarly, 
another group located in South Korea used 
adipose tissue derived mesenchymal stem cells 
(ADMSCs) as a source of stem cell based therapy. 
They indicated that the animal models used in 
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their experiments had improvement cognition 
through increase in acetylcholine [39]. 
Interestingly MSCs can improve AD symptoms 
by other mechanisms. A study published by Shin 
et al in South Korea in 2014 in the journal 
autophagy revealed that MSCs improve the 
survival of neurons in the hippocampus in AD 
rodent models through neuroprotective effects. 
In their AD animal models administration of 
MSCs intravenously increased autosomal 
formation and Aβ clearance [40]. 
Table 3: Novel stem cell treatments in animal models 
Study [37] [38] [39] [40] 
Type of stem 
cell 
Mouse and human 
embryonic stem 
cells 
Rat bone marrow 
derived mesenchymal 
stem cell 
 
Human adipose tissue‐
derived mesenchymal stem 
cells 
Human 
mesenchymal stem 
cells 
Model 5XFAD and 
APP/PS1 AD 
mice models 
AD induced in 
Sprague–Dawley rats 
by administering 
aluminum chloride  
18-month-old ICR mice 
model 
5-week-old ICR 
mice and APP/ 
PSEN1 double 
transgenic mice 
models 
Delivery 
route 
8 x 104 mouse or 
humans BFNC 
progenitors 
injected bilaterally 
into the basal 
forebrain. 
3 x 106 BM-MSCs 
/rat injected 
intravenously 
through the tail vein 
For intravenous 
transplantation 1 x 106 
ADMSCs /100 μl/mouse 
cells were injected and for 
intracerebroventricular 
transplantation 4 x 105 
ADMSCs /2 μl /mouse cells 
were injected. 
1.0 × 106 MSCs 
were intravenously 
injected through the 
tail vein 
Findings ESCs 
differentiated into 
competent 
BFCNs. 
 
The grafts 
differentiated into 
functional mature 
cholinergic 
neurons and 
integrated into the 
basal forebrain 
cholinergic 
projection system. 
 
Mice with cell 
transplants 
showed 
improvements in 
learning and 
memory. 
BM-MSC crossed the 
blood-brain barrier 
and reached affected 
areas of the brain. 
 
The rats that received 
treatment showed an 
increase in 
proliferation of 
choline 
acetyltransferase and 
survivin labelled 
cells. 
 
The brains of rats that 
received treatment 
had a marked 
decrease in Aβ 
accumulation 
Transplanted ADMSCs 
differentiated into neurones 
and intro astrocytes. 
 
The ADMSCs expressed the 
expression of nerve growth 
factor and brain-derived 
neurotrophic factor. 
 
Compared to controls mice 
treated with ADMSCs had 
improved physical and 
cognitive performances.   
MSCs 
administration 
increased 
expression of 
Beclin 1, LC3-II 
and autophagosome 
induction in brain 
tissue 
 
Induction of 
autophagic system 
increased Aβ 
clearance.  
 
MSCs increased 
cellular 
survivability 
through 
neuroprotective 
effects 
 
4 Clinical trials of stem cell therapy 
Before any treatment can be routinely performed 
in the hospital these treatments need to be 
evaluated in clinical trials to assess their efficacy 
and safety. At the moment most of the stem cell-
based therapies clinical trials being conducted in 
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the last 10 years are at the phase I stage (Table 4). 
At this stage the safety and tolerability of the 
treatment are being measured on recruited 
patients diagnosed with the disease.  
 
Table 4: Clinicals trials in the last 10 years 
Trial 
identifier 
NCT01297218 NCT02054208 NCT02600130 NCT02833792 NCT02672306 
Start date February 2011 
 
February 2014 August 2016 June 2016 October 2017 
End date December 2011 July 2019 March 2020 June 2020 October 2019 
Phase I I/IIa I IIa I/II 
Study 
design 
Open label, 
single group 
evaluating safety 
Randomized, 
multiple dose 
cohort study 
Randomized and 
double-blinded 
for assessing 
safety and 
efficacy 
Randomized, 
crossover study 
evaluating 
efficacy and 
safety 
Randomized and 
double blinded 
study assessing 
efficacy and 
safety 
Inclusion 
criteria 
Probable AD by 
NINCDS-
ADRDA criteria, 
positive for Aβ 
by PIB-PET 
(SUV > 1.5) 
Probable AD by 
NINCDS-ADRDA 
criteria, 
positive for Aβ by 
PIB-PET (SUV > 
1.5) or Florbetaben 
PET 
Probable AD by 
NINCDS-
ADRDA 
positive for Aβ 
by PET using 
AMYViD, 
Vizamyl, or 
Neuraceq tracers 
Probable AD by 
NINCDS-
ADRDA criteria, 
positive for Aβ 
by Florbetaben 
PET 
Probable AD by 
NINCDS-
ADRDA criteria, 
MMSE score 
between 10 and 
26 
Type of 
stem cells 
Human 
Umbilical Cord 
Blood Derived 
Mesenchymal 
Stem Cells 
Human Umbilical 
Cord Blood 
Derived 
Mesenchymal 
Stem Cells 
Allogeneic 
Human 
Mesenchymal 
Stem Cell 
Allogeneic 
Human 
Mesenchymal 
Stem Cells 
Umbilical Cord 
Mesenchymal 
Stem Cell 
Subjects 
enrolled 
9 45 38 40 16 
 
Dosage Dose A – 3 x 106 
cells per brain  
DOSE B – 6 x 
106 cells per 
brain 
Dose A – 3 
intraventricular 
injections of 1 x 
107 cells 
Dose B – 3 
intraventricular 
injections of 3 x 
107 cells 
Dose A – 20 x 
106 cells per 
peripheral 
intravenous 
infusion 
Dose B – 100 x 
106 per 
peripheral 
intravenous 
infusion 
1 intravenous 
injection of 1.5 x 
106 per kg of 
body weight 
8 intravenous 
injection of 20 x 
106 cells  
One phase I clinical trial in 2011 conducted at 
Samsung Medical Center, South Korea evaluated 
the safety of using NEUROSTEM®-AD, which 
consists of human umbilical cord blood derived 
mesenchymal stem cells (Trial identifier: 
NCT01297218). In this trial 9 AD diagnosed 
patients were recruited and subjected to 
administration of NEUROSTEM®-AD into the 
hippocampus by stereotactic injection. 3 of these 
patients received low dose of NEUROSTEM®-
AD whilst the remaining 6 patients received high 
dose of NEUROSTEM®-AD. The patients were 
followed for 2 years and showed good tolerability 
without severe adverse side-effects [41]. In 2017 
the Samsung Medical Center started the second 
phase clinical trial of this stem cell-based therapy 
to measure the efficacy of the treatment. It will 
be interesting to see clinical outcome of this trial, 
which is estimated to end in July 2019 (Trial 
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identifier: NCT02054208). Similarly Longeveron 
LLC at United States has started a phase 1 clinical 
trial using allogeneic human mesenchymal stem 
cells (Trial Identifier: NCT02600130). This trial 
will recruit 25 subjects diagnosed with AD to 
investigate the safety and tolerability of the 
treatment. The trial participants will either receive 
high dose, low dose or placebo. 
Moreover in the last 5 years 2 other stem cell 
based treatments have reached the phase II stage. 
One of the clinical trials is using mesenchymal 
stem cells and will assess the efficacy of the 
treatment (Trial Identifier: NCT02833792). This 
trial is expected to end in 2020. Likewise another 
Human Umbilical Cord-Derived Mesenchymal 
Stem Cells phase II trial is being conducted at 
South China Research Center for Stem Cell and 
Regenerative Medicine at China (Trial Identifier: 
NCT02672306). This study will evaluate the 
efficacy of the treatment and is expected to end 
in the last quarter of 2019. 
5 Perspective 
AD is one common form of dementia, affecting 
over 50 million people worldwide and placing a 
huge burden on society [1]. This 
neurodegenerative disease is well characterized 
by extreme atrophy in hippocampus and cerebral 
cortex due to neuronal death. At the moment the 
exact triggers that instigate the neuronal loss is 
controversial. There have been several 
hypotheses postulated; with the common ones 
being amyloid and tau hypotheses. There have 
been several novel treatments proposed agreeing 
with this hypothesis. Unfortunately the clinical 
trials showed no significant benefit or were 
terminated early because of ethical concerns with 
administering treatment to thousands of patients 
that are unlikely to work [11]. The failure of the 
clinical trials raises the following questions: is it 
time to completely abandon this hypothesis or 
shall we try to intervene at the earlier stages of the 
disease? If we want to intervene at the early stages 
of the disease, at the pre-symptomatic stage, we 
need to develop good biomarkers for the early 
phase of this disease.  
Because of the failure of the clinical trials 
following the amyloid hypothesis has encouraged 
researchers to posit new ideas. One approach 
would be to promote neurogenesis by activating 
NSCs niches in SVG and DG of the brain. 
However neurogenesis drastically decreases with 
age and the rate of loss of neurons in AD is 
significantly more dramatic [36]. Also the 
upregulation of NSCs in SVG do not generate all 
neuronal subtypes and thus cannot repopulate 
pyramidal neurons of CA1, which is one of the 
neuronal subtypes affected in AD [42]. Therefore 
the rate of neurogenesis is unlikely to keep up 
with the rate of neuronal loss. Moreover in the 
later phases of AD the NSCs are not expected to 
survive therefore attempting to activate NSCs 
will not lead to any clinical benefit.  
Another approach to treat AD would be 
exogenous repair, such as cell replacement 
therapy derived from stem cells. One source of 
stem cells are ESCs but the spontaneous 
propensity of ESCs to form teratocarcinomas 
and their ability to generate an immune response 
into the host necessitates caution for clinical use 
[43]. The issues of ESCs host rejection can be 
rectified by using an autologous therapeutic 
approach. In this method somatic cells are taken 
from the patient, reprogrammed into stem like 
state in vitro and then transplanted back into the 
patient. Furthermore iPSCs are less tumorigenic 
than ESCs because the mutations acquired during 
reprogramming are mostly benign [44]. However 
the AD risk genes that initially aggravates AD is 
likely to be present in the iPSCs derived cells and 
thus not actually curing the disease.  
Before any of these novel treatments can be 
attempted on humans’ researchers need to test 
them on animal models. Proof of concepts of 
these ideas have elicited encouraging results using 
ESCs as well as MSCs. Studies mentioned in this 
review have shown that stem cell treatments can 
improve learning and memory in rodents. 
However animal models used in these 
experiments obeyed amyloid hypothesis and 
therefore in my opinion do not fully recapitulate 
AD that is observed in humans.  
In the last 10 year there have been several clinical 
trials registered for treating AD using stem cell-
based therapy. Three have reached phase II 
where efficacy of the treatment is evaluated. It is 
too early to state whether stem cells will be 
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routinely used in the clinic because none have 
reached stage III and IV yet and can still fail.  
6 Conclusion 
Alzheimer’s disease (AD) places a huge burden 
on the health agencies all of over the world. At 
the moment there is no cure for AD but it is 
theorized that cell replacement therapy is one 
potential mechanism of treating this disease. This 
review has explored several preclinical studies 
that showed that stem cell-based therapies 
improve cognition and memory in AD models. 
The impressive results from preclinical studies 
have paved the way for clinical trials. It is hoped 
that the information gained from these clinical 
trials will accelerate availability of stem cell-based 
therapies for all hospital patients suffering from 
AD. 
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